Cervical spondylodiscitis caused by Aspergillus in a non-immunocompromised patient: a case report
DOI:
https://doi.org/10.18203/2349-2902.isj20251914Keywords:
Aspergillus, Cervical spine, SpondylodiscitisAbstract
Spondylodiscitis caused by Aspergillus spp. is a rare but serious infection, making it particularly challenging to diagnose and manage. We report a case of a 53-year-old man presenting with neck pain and progressive quadriparesis. Neurological examination revealed power of 3/5 in the upper limbs and 1/5 in the lower limbs, with a modified Nurick grade VI and mJOA score of 9. He had chronic liver and kidney disease but no known immunosuppression. Laboratory investigations showed normal white blood cell (WBC) count, elevated erythrocyte sedimentation rate (ESR) (83 mm/hour), C-reactive protein (CRP) (33 mg/dl), and thrombocytopenia. Initial imaging suggested C5-C6 spondylodiscitis with vertebral destruction and an epidural abscess. A presumptive diagnosis of tubercular spondylodiscitis was made. The patient underwent C5-C7 laminectomy with evacuation of the abscess. Histopathology revealed fungal hyphae of Aspergillus and Candida (PAS and GMS positive). Cultures confirmed Aspergillus spp. He was started on liposomal Amphotericin B and Voriconazole. Due to persistent cord compression on follow-up magnetic resonance imaging (MRI), he underwent C5-C6 corpectomy with iliac crest bone graft fusion and anterior plating. Intraoperatively, C5-C6 vertebrae were destroyed with surrounding inflammatory tissue. Postoperative antifungal therapy continued for two months. This case emphasizes that Aspergillus spondylodiscitis, although rare, should be considered in culture-negative or non-resolving spinal infections, especially in patients with chronic illnesses. Early imaging, histopathology, and timely antifungal therapy with surgical intervention are crucial for favorable outcomes.
Metrics
References
Gamaletsou MN, Rammaert B, Bueno MA, Moriyama B, Sipsas NV, Kontoyiannis DP, et al. Aspergillus osteomyelitis: epidemiology, clinical manifestations, management, and outcome. J Infect. 2014;68(5):478-93. DOI: https://doi.org/10.1016/j.jinf.2013.12.008
Lyons MK, Neal MT, Patel NP, Vikram HR. Progressive Back Pain due to Aspergillus nidulans Vertebral Osteomyelitis in an Immunocompetent Patient: Surgical and Antifungal Management. Case Rep Orthop. 2019;2019:4268468. DOI: https://doi.org/10.1155/2019/4268468
Perna A, Ricciardi L, Fantoni M, Taccari F, Torelli R, Santagada DA, et al. Spontaneous Vertebral Aspergillosis, the State of Art: A Systematic Literature Review. Neurospine. 2021;18(1):23-33. DOI: https://doi.org/10.14245/ns.2040338.169
Aydın Ö, Bektaş B, Aslan A, Yıldırım AN, Arslan F. Voriconazole-treated aspergillus vertebral osteomyelitis in an immunocompetent patient. J Orthop Sci. 2023;28(3):710-2. DOI: https://doi.org/10.1016/j.jos.2020.09.003
Koutserimpas C, Chamakioti I, Zervakis S, Raptis K, Alpantaki K, Kofteridis DP, et al. Non-Candida Fungal Prosthetic Joint Infections. Diagnostics (Basel). 2021;11(8):1410. DOI: https://doi.org/10.3390/diagnostics11081410
Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012;56(1):584-7. DOI: https://doi.org/10.1128/AAC.05394-11
Koutserimpas C, Samonis G, Velivassakis E, Iliopoulou-Kosmadaki S, Kontakis G, Kofteridis DP. Candida glabrata prosthetic joint infection, successfully treated with anidulafungin: A case report and review of the literature. Mycoses. 2018;61(4):266-9. DOI: https://doi.org/10.1111/myc.12736
Nett JE, Andes DR. Antifungal Agents. Infect Dis Clin N Am. 2016;30:51-83. DOI: https://doi.org/10.1016/j.idc.2015.10.012
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15. DOI: https://doi.org/10.1056/NEJMoa020191
Hamill RJ. Amphotericin B. Formulations: A Comparative Review of Efficacy and Toxicity. Drugs. 2013;73:919-34. DOI: https://doi.org/10.1007/s40265-013-0069-4